The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

The Future of Pharmacological Therapy for Heart Failure

(2010) Yusuke Sata et al.   CIRCULATION JOURNAL

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

(2010) Monique E Cho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias

(2010) Duy T. Nguyen et al.   HEART RHYTHM

Inhibition of Matrix Deposition: A New Strategy for Prevention of Restenosis After Balloon Angioplasty

(2010) Andreas Backes et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

New pharmacological treatments for improving renal outcomes in diabetes

(2010) Anne-Emilie Declèves et al.   Nature Reviews Nephrology

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

(2010) Arata Azuma   Expert Review of Respiratory Medicine

Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis

(2009) Fabio Grizzi   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates

(2009) Yasukatsu Izumi et al.   HYPERTENSION RESEARCH

Pirfenidone Is Renoprotective in Diabetic Kidney Disease

(2009) S. P. RamachandraRao et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone

(2008) Catherine A. Lemarié et al.   JOURNAL OF MOLECULAR MEDICINE-JMM